Free tool
Upcoming earnings calendar
See who reports in the next 30, 60 or 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
See who reports in the next 30, 60 or 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
See who reports in the Americas in the next 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
127 companies reporting in the next 90 days. Clear filters
Data as of Aug 27, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | 1M return | |
|---|---|---|---|---|---|
| Wednesday, Sep 16 · in 20 days · 1 company | |||||
| RZLT | Rezolute, Inc. | Rare disease | $485.31M | +2.44% | |
| Wednesday, Sep 23 · in 27 days · 1 company | |||||
| INM | InMed Pharmaceuticals Inc. | Rare disease | $7.64M | −14.37% | |
| Thursday, Oct 22 · in 56 days · 1 company | |||||
| ARGX | argenx SE | Rare disease | $65.51B | +20.05% | |
| Monday, Oct 26 · in 60 days · 1 company | |||||
| BMRN | BioMarin Pharmaceutical Inc. | Rare disease | |||
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock. Looking for a name that isn't listed? Jump straight to it:
| $12.70B |
| +5.70% |
| Tuesday, Oct 27 · in 61 days · 2 companies | |||||
| KNSA | Kiniksa Pharmaceuticals International, plc | Rare disease | $6.05B | −0.96% | |
| ARQT | Arcutis Biotherapeutics, Inc. | Rare disease | $3.12B | −11.54% | |
| Wednesday, Oct 28 · in 62 days · 3 companies | |||||
| BBIO | BridgeBio Pharma, Inc. | Rare disease | $15.52B | −7.22% | |
| DBVT | DBV Technologies S.A. | Rare disease | $940.80M | +7.56% | |
| RFL | Rafael Holdings, Inc. | Rare disease | $119.08M | +9.05% | |
| Thursday, Oct 29 · in 63 days · 5 companies | |||||
| ALNY | Alnylam Pharmaceuticals, Inc. | Rare disease | $32.12B | −17.13% | |
| INSM | Insmed Incorporated | Rare disease | $27.16B | +19.46% | |
| TVTX | Travere Therapeutics, Inc. | Rare disease | $6.24B | +20.05% | |
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | Rare disease | $2.03B | −5.56% | |
| FULC | Fulcrum Therapeutics, Inc. | Rare disease | $294.51M | +3.76% | |
| Monday, Nov 2 · in 67 days · 2 companies | |||||
| VRTX | Vertex Pharmaceuticals Incorporated | Rare disease | $138.63B | +11.60% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | Rare disease | $2.51B | +0.92% | |
| Tuesday, Nov 3 · in 68 days · 8 companies | |||||
| KYMR | Kymera Therapeutics, Inc. | Rare disease | $10.53B | +18.26% | |
| RYTM | Rhythm Pharmaceuticals, Inc. | Rare disease | $7.78B | +3.54% | |
| LQDA | Liquidia Corporation | Rare disease | $6.31B | −17.81% | |
| RARE | Ultragenyx Pharmaceutical Inc. | Rare disease | $2.61B | +1.77% | |
| STOK | Stoke Therapeutics, Inc. | Rare disease | $2.14B | +12.59% | |
| EPRX | Eupraxia Pharmaceuticals Inc. | Rare disease | $490.26M | +21.80% | |
| EPRX.TO | Eupraxia Pharmaceuticals Inc. | Rare disease | $487.17M | +20.23% | |
| CPIX | Cumberland Pharmaceuticals Inc. | Rare disease | $130.35M | +69.86% | |
| Wednesday, Nov 4 · in 69 days · 13 companies | |||||
| JAZZ | Jazz Pharmaceuticals plc | Rare disease | $16.89B | −2.97% | |
| CORT | Corcept Therapeutics Incorporated | Rare disease | $12.95B | +27.19% | |
| IONS | Ionis Pharmaceuticals, Inc. | Rare disease | $10.56B | +14.58% | |
| MIRM | Mirum Pharmaceuticals, Inc. | Rare disease | $5.98B | −12.22% | |
| ADMA | ADMA Biologics, Inc. | Rare disease | $2.16B | +9.56% | |
| TYRA | Tyra Biosciences, Inc. | Rare disease | $1.56B | −15.09% | |
| ZVRA | Zevra Therapeutics, Inc. | Rare disease | $697.17M | +20.66% | |
| AQST | Aquestive Therapeutics, Inc. | Rare disease | $676.51M | +43.35% | |
| UPB | Upstream Bio, Inc. | Rare disease | $390.52M | +11.41% | |
| KROS | Keros Therapeutics, Inc. | Rare disease | $220.48M | +10.43% | |
| GOSS | Gossamer Bio, Inc. | Rare disease | $85.01M | −15.17% | |
| SCYX | SCYNEXIS, Inc. | Rare disease | $56.41M | +56.20% | |
| MCRB | Seres Therapeutics, Inc. | Rare disease | $47.81M | −0.83% | |
| Thursday, Nov 5 · in 70 days · 27 companies | |||||
| CYTK | Cytokinetics, Incorporated | Rare disease | $11.01B | −0.31% | |
| PTGX | Protagonist Therapeutics, Inc. | Rare disease | $9.80B | +10.71% | |
| CRNX | Crinetics Pharmaceuticals, Inc. | Rare disease | $9.00B | +1.17% | |
| DNTH | Dianthus Therapeutics, Inc. | Rare disease | $6.13B | +9.01% | |
| PTCT | PTC Therapeutics, Inc. Common Stock | Rare disease | $6.07B | −3.58% | |
| DYN | Dyne Therapeutics, Inc. | Rare disease | $4.92B | +1.78% | |
| EWTX | Edgewise Therapeutics, Inc. | Rare disease | $4.80B | +9.99% | |
| AMLX | Amylyx Pharmaceuticals, Inc. | Rare disease | $4.13B | +89.67% | |
| IRON | Disc Medicine, Inc. | Rare disease | $3.17B | +10.74% | |
| VRDN | Viridian Therapeutics, Inc. | Rare disease | $2.75B | +24.35% | |
| VERA | Vera Therapeutics, Inc. | Rare disease | $2.65B | +10.50% | |
| MAZE | Maze Therapeutics, Inc. | Rare disease | $1.69B | +6.10% | |
| XERS | Xeris Biopharma Holdings, Inc. | Rare disease | $1.58B | +5.34% | |
| TRAX | First Tracks Biotherapeutics, Inc. | Rare disease | $1.58B | +5.59% | |
| MLTX | MoonLake Immunotherapeutics | Rare disease | $1.32B | −16.52% | |
| DSGN | Design Therapeutics, Inc. | Rare disease | $975.65M | +31.34% | |
| SLN | Silence Therapeutics plc | Rare disease | $840.94M | +17.14% | |
| GYRE | Gyre Therapeutics, Inc. | Rare disease | $705.12M | +11.02% | |
| TECX | Tectonic Therapeutic, Inc. | Rare disease | $703.19M | +20.70% | |
| LRMR | Larimar Therapeutics, Inc. | Rare disease | $432.15M | +8.88% | |
| XFOR | X4 Pharmaceuticals, Inc. | Rare disease | $412.45M | +6.11% | |
| PRQR | ProQR Therapeutics N.V. | Rare disease | $331.63M | +33.52% | |
| TRDA | Entrada Therapeutics, Inc. | Rare disease | $296.70M | +20.07% | |
| SION | Sionna Therapeutics, Inc. | Rare disease | $282.58M | −86.75% | |
| IVVD | Invivyd, Inc. | Rare disease | $265.78M | +52.06% | |
| SIGA | SIGA Technologies, Inc. | Rare disease | $220.58M | −8.08% | |
| ATYR | aTyr Pharma, Inc. | Rare disease | $54.05M | +11.54% | |
| Friday, Nov 6 · in 71 days · 1 company | |||||
| ANIP | ANI Pharmaceuticals, Inc. | Rare disease | $1.71B | −8.00% | |
| Monday, Nov 9 · in 74 days · 13 companies | |||||
| ROIV | Roivant Sciences Ltd. | Rare disease | $26.55B | +8.60% | |
| IMVT | Immunovant, Inc. | Rare disease | $9.07B | +12.83% | |
| CLDX | Celldex Therapeutics, Inc. | Rare disease | $3.19B | +14.02% | |
| AUPH | Aurinia Pharmaceuticals Inc. | Rare disease | $2.20B | +10.56% | |
| SEPN | Septerna, Inc. | Rare disease | $1.88B | +18.49% | |
| FBRX | Forte Biosciences, Inc. | Rare disease | $1.63B | +0.44% | |
| WVE | Wave Life Sciences, Inc. | Rare disease | $1.03B | −11.21% | |
| ANNX | Annexon, Inc. | Rare disease | $946.00M | +0.40% | |
| IRWD | Ironwood Pharmaceuticals, Inc. | Rare disease | $708.88M | +12.89% | |
| KMDA | Kamada Ltd. Ordinary Shares | Rare disease | $483.48M | +18.70% | |
| IFRX | InflaRx N.V. | Rare disease | $356.63M | +43.20% | |
| AKBA | Akebia Therapeutics, Inc. | Rare disease | $251.20M | −28.62% | |
| MREO | Mereo BioPharma Group plc | Rare disease | $44.39M | −10.03% | |
| Tuesday, Nov 10 · in 75 days · 4 companies | |||||
| MLYS | Mineralys Therapeutics, Inc. | Rare disease | $2.28B | −3.93% | |
| SPRY | ARS Pharmaceuticals, Inc. | Rare disease | $568.84M | +6.35% | |
| INO | Inovio Pharmaceuticals, Inc. | Rare disease | $134.42M | +26.21% | |
| JSPR | Jasper Therapeutics, Inc. | Rare disease | $23.96M | +13.43% | |
| Wednesday, Nov 11 · in 76 days · 8 companies | |||||
| ORKA | Oruka Therapeutics, Inc. | Rare disease | $6.58B | +9.94% | |
| PVLA | Palvella Therapeutics, Inc. | Rare disease | $2.22B | +8.04% | |
| SVRA | Savara Inc. | Rare disease | $1.15B | +5.25% | |
| AVIR | Atea Pharmaceuticals, Inc. | Rare disease | $441.93M | +22.17% | |
| PEPG | PepGen Inc. | Rare disease | $237.21M | +75.96% | |
| ARMP | Armata Pharmaceuticals, Inc. | Rare disease | $202.64M | +15.22% | |
| MDP.TO | Medexus Pharmaceuticals Inc. | Rare disease | $117.29M | +7.02% | |
| PYPD | PolyPid Ltd. | Rare disease | $103.79M | +36.27% | |
| Thursday, Nov 12 · in 77 days · 10 companies | |||||
| SRRK | Scholar Rock Holding Corporation | Rare disease | $7.31B | +21.61% | |
| MANE | Veradermics, Incorporated | Rare disease | $4.29B | −7.84% | |
| PHVS | Pharvaris N.V. | Rare disease | $2.60B | +9.97% | |
| TRVI | Trevi Therapeutics, Inc. | Rare disease | $2.55B | −2.77% | |
| NKTR | Nektar Therapeutics | Rare disease | $2.52B | +4.24% | |
| ZBIO | Zenas BioPharma, Inc. | Rare disease | $2.15B | +2.32% | |
| ETON | Eton Pharmaceuticals, Inc. | Rare disease | $1.79B | +34.20% | |
| OMER | Omeros Corporation | Rare disease | $1.40B | +61.52% | |
| JBIO | Jade Biosciences, Inc. | Rare disease | $1.39B | +8.27% | |
| AVTX | Avalo Therapeutics, Inc. | Rare disease | $1.10B | +5.28% | |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India). Reporting dates are public estimates and can shift.